AR129994A1 - SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3PGLU Ab Y USOS DE ESTAS - Google Patents
SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3PGLU Ab Y USOS DE ESTASInfo
- Publication number
- AR129994A1 AR129994A1 ARP230101919A ARP230101919A AR129994A1 AR 129994 A1 AR129994 A1 AR 129994A1 AR P230101919 A ARP230101919 A AR P230101919A AR P230101919 A ARP230101919 A AR P230101919A AR 129994 A1 AR129994 A1 AR 129994A1
- Authority
- AR
- Argentina
- Prior art keywords
- n3pglu
- pharmaceutical solutions
- antibodies
- antibodies pharmaceutical
- solutions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263369033P | 2022-07-21 | 2022-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129994A1 true AR129994A1 (es) | 2024-10-23 |
Family
ID=87576063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101919A AR129994A1 (es) | 2022-07-21 | 2023-07-21 | SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3PGLU Ab Y USOS DE ESTAS |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP4558166A1 (fr) |
| JP (1) | JP2025525587A (fr) |
| KR (1) | KR20250037554A (fr) |
| CN (1) | CN119604302A (fr) |
| AR (1) | AR129994A1 (fr) |
| AU (1) | AU2023309007A1 (fr) |
| CA (1) | CA3261418A1 (fr) |
| CL (1) | CL2025000145A1 (fr) |
| CO (1) | CO2025000508A2 (fr) |
| CR (1) | CR20250023A (fr) |
| DO (1) | DOP2025000005A (fr) |
| IL (1) | IL318102A (fr) |
| JO (1) | JOP20250013A1 (fr) |
| MA (1) | MA71558A (fr) |
| MX (1) | MX2025000820A (fr) |
| PE (1) | PE20250785A1 (fr) |
| TW (1) | TW202421188A (fr) |
| WO (1) | WO2024020470A1 (fr) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3042917T3 (pl) * | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie |
-
2023
- 2023-07-20 EP EP23755273.2A patent/EP4558166A1/fr active Pending
- 2023-07-20 CR CR20250023A patent/CR20250023A/es unknown
- 2023-07-20 CN CN202380055471.XA patent/CN119604302A/zh active Pending
- 2023-07-20 AU AU2023309007A patent/AU2023309007A1/en active Pending
- 2023-07-20 KR KR1020257005184A patent/KR20250037554A/ko active Pending
- 2023-07-20 MA MA71558A patent/MA71558A/fr unknown
- 2023-07-20 WO PCT/US2023/070540 patent/WO2024020470A1/fr not_active Ceased
- 2023-07-20 JP JP2025502865A patent/JP2025525587A/ja active Pending
- 2023-07-20 CA CA3261418A patent/CA3261418A1/fr active Pending
- 2023-07-20 PE PE2025000205A patent/PE20250785A1/es unknown
- 2023-07-20 IL IL318102A patent/IL318102A/en unknown
- 2023-07-21 TW TW112127310A patent/TW202421188A/zh unknown
- 2023-07-21 AR ARP230101919A patent/AR129994A1/es unknown
-
2025
- 2025-01-16 CL CL2025000145A patent/CL2025000145A1/es unknown
- 2025-01-17 CO CONC2025/0000508A patent/CO2025000508A2/es unknown
- 2025-01-20 MX MX2025000820A patent/MX2025000820A/es unknown
- 2025-01-20 DO DO2025000005A patent/DOP2025000005A/es unknown
- 2025-01-21 JO JOJO/P/2025/0013A patent/JOP20250013A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20250785A1 (es) | 2025-03-14 |
| DOP2025000005A (es) | 2025-02-28 |
| CO2025000508A2 (es) | 2025-02-04 |
| WO2024020470A1 (fr) | 2024-01-25 |
| JP2025525587A (ja) | 2025-08-05 |
| JOP20250013A1 (ar) | 2025-01-21 |
| CA3261418A1 (fr) | 2024-01-25 |
| AU2023309007A1 (en) | 2025-01-30 |
| CR20250023A (es) | 2025-02-17 |
| CN119604302A (zh) | 2025-03-11 |
| MA71558A (fr) | 2025-05-30 |
| TW202421188A (zh) | 2024-06-01 |
| MX2025000820A (es) | 2025-03-07 |
| IL318102A (en) | 2025-02-01 |
| KR20250037554A (ko) | 2025-03-17 |
| EP4558166A1 (fr) | 2025-05-28 |
| CL2025000145A1 (es) | 2025-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0209777A (pt) | Formulações lìquidas estáveis | |
| GT200900268A (es) | Polipeptidos de factor vii modificados y usos de los mismos . | |
| PA8479201A1 (es) | Derivados del acido hidroxi-pipecolato hidroxamico | |
| JOP20240288A1 (ar) | أجسام مضادة لـ ror1 ومتقارنات الأجسام المضادة، تركيبات تحتوي على أجسام مضادة لـ ror1 أو متقارنات الأجسام المضادة، وطرق تصنيع واستخدام الأجسام المضادة لـ ror1 ومتقارنات الأجسام المضادة | |
| RU2011115406A (ru) | Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера | |
| BRPI0518101A (pt) | métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso | |
| ATE407928T1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
| BR0308429A (pt) | Aroilpiridinonas monocìclicas como agentes antiinflamatórios | |
| BRPI0410684A (pt) | uso de um peptìdio conjugado a uma proteìna que age como um imunógeno para a produção de anticorpos capazes de reconhecer especificamente qualquer uma das variantes predominantes do peptìdeo beta amilóide aß40 e aß42 na preparação de um medicamento para a prevenção e/ou o tratamento de uma doença e uso de um anticorpo ou um fragmento ativo ou o derivado de um anticorpo que reconhece especificamente qualquer uma das variantes predominantes do peptìdio beta amilóide, aß40 e aß42, na preparação de um medicamento para prevenção e/ou tratamento de uma doença | |
| ES2182107T3 (es) | Uso en una composicion de un extracto de al menos una labiada del genero rosmarinarus, cultivado in vitro. | |
| MX9705349A (es) | Anticuerpo monoclonal 1a7 y su uso para el tratamiento de melanona y carcinoma de celulas pequeñas. | |
| JOP20190155B1 (ar) | مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم | |
| BRPI0517500B8 (pt) | composto, uso de uma composição, composição farmacêutica, composição cosmética, usos não-terapêuticos de uma composição cosmética e processo cosmético para melhorar a aparência da pele | |
| AR029619A1 (es) | Vacuna | |
| ES2156107T3 (es) | Un fgf-4 no glicosilado y composiciones que lo contienen. | |
| EA201001288A1 (ru) | Лечение гипертонии 25-гидроксивитамином d3 | |
| AR057239A1 (es) | Inmunoglobulinas | |
| BR0311866A (pt) | Composições de saponinas ou sapogeninas para terapia de câncer | |
| AR129994A1 (es) | SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3PGLU Ab Y USOS DE ESTAS | |
| WO2023081194A3 (fr) | Méthodes de traitement de la maladie d'alzheimer | |
| JOP20250172A1 (ar) | مُقترنات الأدوية والأجسام المضادة لـ cd70 | |
| MX2022006674A (es) | Composiciones de celulas t reguladoras (treg) y metodos para tratar enfermedades neurodegenerativas. | |
| MX2021015292A (es) | Interacciones terapeuticas de leucometiltioninio. | |
| BR112021016795A8 (pt) | Administração de inibidor de enzima de ativação de sumo e inibidores de checkpoint | |
| CL2023003209A1 (es) | Composición farmacéutica de pembrolizumab y su uso |